Cytoreductive surgery and HIPEC for malignant ascites from colorectal cancer - a randomized study. Issue 33 (14th August 2020)

• Record Type: Journal Article
• Authors: Ba, Mingchen; Chen, Cheng; Long, Hui; Gong, Yuanfeng; Wu, Yinbin; Lin, Kunpeng; Tu, Yinuo; Zhang, Bohuo; Wu, Wanbo
• Other Names: Kok. Victor C. section editor.
• Is Part Of: Medicine. Volume 99:Issue 33(2020)
• Publication Date: 2020-08-14
• Subjects: ascites -- colorectal cancer -- cytoreductive surgery -- hyperthermic intraperitoneal chemotherapy -- peritoneal carcinomatosis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000021546
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Introduction: The efficacy of different timings of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in controlling malignant ascites caused by peritoneal carcinomatosis of colorectal cancer (CRC) is not well defined. The study aims to investigate the clinical efficacy and safety of different timings of CRS with HIPEC for malignant ascites caused by peritoneal carcinomatosis from CRC. Materials and Methods: This was a preliminary randomized controlled study performed at the Intracelom Hyperthermic Perfusion Therapy Center of the Cancer Hospital of Guangzhou Medical University (China) from December 2008 to December 2016. The patients were randomized to: CRS, followed by HIPEC (CRS+HIPEC; n = 14), and ultrasound-guided HIPEC, followed by CRS 1 to 2 weeks later (HIPEC+ delayed cytoreductive surgery (dCRS) group, n = 14). The endpoints were complete remission rate of ascites, successful complete CRS rate, and overall survival. Results: Malignant ascites in all patients showed complete remission; the total effective rate was 100%. Complete CRS was not feasible in any patient. The median follow-up of the 2 groups was 41.9 and 42.3 months in the CRS+HIPEC and HIPEC+dCRS groups, respectively. Overall survival was 14.5 (95%CI: 7–19 months) and 14.3 months (95%CI: 4–21 months) ( P > .05). The adverse effects of HIPEC were manageable. Conclusions: CRS+HIPEC and HIPEC+dCRS have the same efficacy in controlling malignant ascites caused by CRC and peritoneal carcinomatosis. The timing of CRS and HIPEC does not prolong the survival of patients with peritoneal carcinomatosis from CRC, even when a complete CRS is not feasible.